Medicines Value Calculators
Overview
These calculators illustrate potential savings from selected changes in prescribing. Many of the examples shown involve relatively simple switches from one formulation to another, with no change in drug or total daily dose. Others show the savings that could be made from switching to effective alternatives from the same therapeutic class.
Frequency
Quarterly
Data period
September 2026
Eculizumab for the treatment and prevention of antibody-mediated rejection in heart transplantation
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Monthly formulary amendments – September 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in September 2025.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Regional prescribing position; North West region.
September update
The purpose of this bulletin is to provide the regional team with an overview of the prescribing position in the North West region, the progress made in the National Medicines Optimisation Opportunities and the wider focus on prescribing for the North West ICBs.
Naloxegol and naldemedine for post-operative ileus following radical cystectomy
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Intralesional rituximab for localised pemphigus
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Monthly Horizon Scanning Report – September 2025
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals
Prescribing Update Newsletter – September 2024
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition focuses on Prescribing Data Surveillance, the updated Inhaler Carbon Impact Assessment Tool, and our recently published Safer Medication Use publication looking at propranolol in the treatment of anxiety. It also includes information on some key medicines availability issues, the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources, and another in the series of “Meet the Team” where you can get to know the people behind the work we do.
View the preview below on desktop, or click here to download a copy.
Monthly formulary amendments – September 2024
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in September 2024.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Safer Medication Use – Propranolol in the treatment of anxiety
Overview
Safer Medication Use is a bulletin series jointly produced by the Regional Drug and Therapeutics Centre and the Yellow Card Centre Northern and Yorkshire, which aims to promote safer prescribing. It discusses specific drug related safety problems, provides guidance to ensure safe, appropriate prescribing and raises awareness of adverse drug reaction detection and reporting.
Propranolol is increasingly used for the treatment of anxiety. However, several recent critical incidents have raised concerns that there may still be a lack of awareness amongst prescribers over the risks associated with propranolol in overdose. This report aims to raise awareness of the potential toxicity of propranolol in overdose and highlight a specific group of patients who may be at an increased risk of using propranolol for self-harm.